Rajasthan Antibiotics Limited (RAL), which is a leading pharmaceutical company in North India is planning to raise an amount of Rs. 50 crores through venture capital (VC) funding by August-September 2017.
BIORx Venture Advisors Pvt Limited (BIORx) has been mandated to syndicate funds. The funding would be pumped into company expansion through Greenfield and Brownfield. BIORx works as a financial and strategic partner for the life-sciences industry.
In the past 25 years, RAL has grown both in size and reputation to become the nation’s largest producer of injectable antibiotics. The company has a diversified product mix that largely caters to two therapeutic segments, namely, Anti-Infective and gastroenterology.
Mr. Ashish Pruthi, MD, RAL, said, “Our next target is to generate a revenue of INR 500 crores by 2020 and strengthening our position in the ever-growing niche segment of Steriles.”
